APM
Avidity Partners Management Portfolio holdings
AUM
$499M
This Quarter Return
-2.89%
1 Year Return
+3.47%
3 Year Return
+181.12%
5 Year Return
+409%
10 Year Return
–
AUM
$3.01B
AUM Growth
+$3.01B
(-30%)
Cap. Flow
-$880M
Cap. Flow
% of AUM
-29.21%
Top 10 Holdings %
Top 10 Hldgs %
32.92%
Holding
106
New
21
Increased
16
Reduced
41
Closed
22
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$97.9M |
| 2 |
Becton Dickinson
BDX
|
$71.3M |
| 3 |
Zoetis
ZTS
|
$67.8M |
| 4 |
Merck
MRK
|
$63.8M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
$61.9M |
Top Sells
| 1 |
United Therapeutics
UTHR
|
$218M |
| 2 |
argenx
ARGX
|
$128M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
$125M |
| 4 |
Boston Scientific
BSX
|
$120M |
| 5 |
Neurocrine Biosciences
NBIX
|
$97.6M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Avidity Biosciences
RNA
$6.12B
| $19.4M | 0.64% |
1,265,545
-2,009,455
| -61% | -$30.8M |
|
52
Vaxcyte
PCVX
$4.17B
| $19.1M | 0.63% |
510,000
-1,105,400
| -68% | -$41.4M |
|
53
Arcutis Biotherapeutics
ARQT
$1.91B
| $17.9M | 0.59% |
1,628,500
-126,500
| -7% | -$1.39M |
|
|
VRNA
54
Verona Pharma
VRNA
$9.18B
| $17.6M | 0.59% |
+878,800
| New | +$17.6M |
|
|
PNT
55
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $17.5M | 0.58% |
2,411,600
-20,800
| -0.9% | -$151K |
|
56
DexCom
DXCM
$30.9B
| $17.2M | 0.57% |
148,000
-608,800
| -80% | -$70.7M |
|
57
BridgeBio Pharma
BBIO
$9.91B
| $16.6M | 0.55% |
+1,000,000
| New | +$16.6M |
|
58
Immunovant
IMVT
$2.91B
| $16.2M | 0.54% |
+1,043,000
| New | +$16.2M |
|
59
Intellia Therapeutics
NTLA
$1.26B
| $15.5M | 0.52% |
417,000
-221,200
| -35% | -$8.24M |
|
60
Caribou Biosciences
CRBU
$176M
| $14.6M | 0.49% |
2,758,600
-124,000
| -4% | -$658K |
|
61
Phathom Pharmaceuticals
PHAT
$843M
| $14.6M | 0.49% |
2,048,600
+148,600
| +8% | +$1.06M |
|
62
Mersana Therapeutics
MRSN
$34.8M
| $14.1M | 0.47% |
+3,433,233
| New | +$14.1M |
|
63
Natera
NTRA
$23B
| $13.9M | 0.46% |
249,900
-1,549,000
| -86% | -$86M |
|
64
Twist Bioscience
TWST
$1.57B
| $12.4M | 0.41% |
819,000
+208,000
| +34% | +$3.14M |
|
65
Collegium Pharmaceutical
COLL
$1.25B
| $9.25M | 0.31% |
385,500
+347,602
| +917% | +$8.34M |
|
66
Cytokinetics
CYTK
$5.98B
| $8.87M | 0.29% |
252,000
-168,700
| -40% | -$5.94M |
|
|
ALPN
67
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $7.64M | 0.25% |
989,500
-38,700
| -4% | -$299K |
|
|
KNTE
68
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $7.25M | 0.24% |
1,160,000
-52,700
| -4% | -$329K |
|
69
AN2 Therapeutics
ANTX
$35.3M
| $7.14M | 0.24% |
723,200
-20,400
| -3% | -$201K |
|
70
Compass Therapeutics
CMPX
$466M
| $5.97M | 0.2% |
1,825,000
-175,000
| -9% | -$572K |
|
71
Altimmune
ALT
$325M
| $5.55M | 0.18% |
1,315,200
-2,674,800
| -67% | -$11.3M |
|
72
Geron
GERN
$893M
| $4.62M | 0.15% |
+2,128,000
| New | +$4.62M |
|
73
Century Therapeutics
IPSC
$40.4M
| $4.4M | 0.15% |
1,268,100
-35,500
| -3% | -$123K |
|
74
Sangamo Therapeutics
SGMO
$161M
| $4.35M | 0.14% |
2,470,000
-278,300
| -10% | -$490K |
|
75
Praxis Precision Medicines
PRAX
$980M
| $3.46M | 0.12% |
+4,281,700
| New | +$3.46M |
|